scholarly journals Predictive significance of thyroid transcription factor-1 expression in patients with non-squamous non-small cell lung cancer with wild-type epidermal growth factor receptor treated with erlotinib

2016 ◽  
Vol 5 (1) ◽  
pp. 14-18 ◽  
Author(s):  
YOSHIRO NAKAHARA ◽  
YUKIO HOSOMI ◽  
MAKOTO SAITO ◽  
MASUMI OGAWA ◽  
TSUNEKAZU HISHIMA ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Epidermal Growth Factor Receptor ◽  
Growth Factor Receptor ◽  
Small Cell ◽  
Wild Type ◽  
Small Cell Lung ◽  
Thyroid Transcription Factor 1 ◽  
Thyroid Transcription Factor ◽  
Epidermal Growth ◽  
Transcription Factor 1

Synthesis of (-)-epigallocatechin-3-gallate derivative containing a triazole ring and combined with cisplatin/paclitaxel inhibits NSCLC cancer cells by decreasing phosphorylation of the EGFR

2020 ◽  
Vol 44 (9-10) ◽  
pp. 586-591
Author(s):  
Cheng-Ting Zi ◽  
Pei-Yuan Sun ◽  
Ning Zhang ◽  
Han Tang ◽  
Hao-Nang Yang ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Epidermal Growth Factor Receptor ◽  
Growth Factor ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Growth Factor Receptor ◽  
Small Cell ◽  
Wild Type ◽  
Small Cell Lung ◽  
Epidermal Growth

Non-small-cell lung cancer is one of the principal causes of cancer-related death around the world. Chemotherapy is commonly used to treat wild type of epidermal growth factor receptor non-small-cell lung cancer. (-)-Epigallocatechin-3-gallate is the most abundant and active catechin. However, (-)-epigallocatechin-3-gallate has limited clinical application due to its poor stability and absorption. Herein, we report that a glycosylated azide undergoes a click reaction with the terminal alkyne of (-)-epigallocatechin-3-gallate to yield a triazole-linked glucose-(-)-epigallocatechin-3-gallate derivative and have evaluated its in vitro anticancer activity against human non-small-cell lung cancer cells using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay. The product inhibits human non-small-cell lung cancer cell lines with wild type of epidermal growth factor receptor and in combination with cisplatin/paclitaxel results in more pronounced proliferation inhibition than when used alone. Stability investigations indicates that the conjugated glucose residue can improve the stability of the (-)-epigallocatechin-3-gallate scaffold. Our studies suggest that the combination of the glucose-(-)-epigallocatechin-3-gallate derivative and chemotherapeutic drugs may provide a novel strategy for the treatment of non-small-cell lung cancer.

scholarly journals Evaluation of erlotinib for the treatment of patients with non-small cell lung cancer with epidermal growth factor receptor wild type

2017 ◽  
Vol 14 (1) ◽  
pp. 306-312 ◽  
Author(s):  
Fumihiko Hirai ◽  
Makoto Edagawa ◽  
Shinichiro Shimamatsu ◽  
Ryo Toyozawa ◽  
Gouji Toyokawa ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Epidermal Growth Factor Receptor ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Small Cell Lung Cancer ◽  
Growth Factor Receptor ◽  
Small Cell ◽  
Wild Type ◽  
Small Cell Lung ◽  
Epidermal Growth

scholarly journals Angiogenesis and epidermal growth factor receptor inhibitors in non-small cell lung cancer

2020 ◽  
Vol 1 (2) ◽  
pp. 117-130
Author(s):  
Giuliano Palumbo ◽  
Giovanna Giovanna Esposito ◽  
Guido Carillio ◽  
Anna Manzo ◽  
Agnese Montanino ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Epidermal Growth Factor Receptor ◽  
Growth Factor Receptor ◽  
Progression Free Survival ◽  
Small Cell ◽  
Wild Type ◽  
Small Cell Lung ◽  
Free Survival ◽  
Pretreated Patients ◽  
Epidermal Growth

Abstract Several preclinical studies suggested a potential benefit from combined treatment with inhibitors of epidermal growth factor receptor (EGFR) and angiogenesis, both effective in patients with advanced non-small-cell lung cancer (NSCLC). In pretreated patients with advanced EGFR wild type NSCLC, bevacizumab plus erlotinib improved progression-free survival as second-line therapy in the BeTa study and as maintenance therapy in the ATLAS trial, although the benefit was modest and did not translate into an advantage in overall survival. Disappointing results were reported with oral VEGF inhibitors plus erlotinib in pretreated patients with EGFR wild type NSCLC. On the contrary, erlotinib plus bevacizumab or ramucirumab showed a clinically relevant improvement of progression-free survival in naïve patients with EGFR mutations, leading to the approval of these two regimens as first-line treatment of NSCLC patients with EGFR mutant tumors. Several clinical studies are evaluating the feasibility and activity of osimertinib plus bevacizumab or ramucirumab. However, limits that could affect its use in clinical practice are the need of an intravenous infusion for angiogenesis inhibitors, the increased incidence of treatment associated adverse events, the exclusion of patients with tumors located in central position or at risk of hemorrhage. The identification of predictive biomarkers is an important goal of research to optimize the combined use of these agents. Keywords Lung cancer, angiogenesis, tyrosine kinase inhibitor, erlotinib, bevacizumab

Sign in / Sign up

Export Citation Format

Share Document